- Home
- OBK vs AUPH Comparison
OBK vs AUPH Comparison
Compare OBK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBK
- AUPH
- Stock Information
- Founded
- OBK 1912
- AUPH 1993
- Country
- OBK United States
- AUPH Canada
- Employees
- OBK N/A
- AUPH N/A
- Industry
- OBK Major Banks
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- OBK Finance
- AUPH Health Care
- Exchange
- OBK Nasdaq
- AUPH Nasdaq
- Market Cap
- OBK 1.1B
- AUPH 1.1B
- IPO Year
- OBK 2018
- AUPH 1999
- Fundamental
- Price
- OBK $37.23
- AUPH $8.86
- Analyst Decision
- OBK Buy
- AUPH Strong Buy
- Analyst Count
- OBK 5
- AUPH 2
- Target Price
- OBK $42.20
- AUPH $11.50
- AVG Volume (30 Days)
- OBK 160.9K
- AUPH 1.9M
- Earning Date
- OBK 07-23-2025
- AUPH 07-31-2025
- Dividend Yield
- OBK 1.59%
- AUPH N/A
- EPS Growth
- OBK N/A
- AUPH N/A
- EPS
- OBK 2.43
- AUPH 0.27
- Revenue
- OBK $351,348,000.00
- AUPH $247,295,000.00
- Revenue This Year
- OBK $13.16
- AUPH $12.15
- Revenue Next Year
- OBK $6.03
- AUPH $18.31
- P/E Ratio
- OBK $15.55
- AUPH $33.04
- Revenue Growth
- OBK 2.92
- AUPH 29.20
- 52 Week Low
- OBK $28.80
- AUPH $5.20
- 52 Week High
- OBK $41.17
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- OBK 62.24
- AUPH 64.10
- Support Level
- OBK $36.94
- AUPH $7.36
- Resistance Level
- OBK $38.05
- AUPH $9.10
- Average True Range (ATR)
- OBK 0.83
- AUPH 0.44
- MACD
- OBK 0.10
- AUPH 0.10
- Stochastic Oscillator
- OBK 75.29
- AUPH 89.53
About OBK Origin Bancorp Inc.
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.